Association between Thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study.

Zhang J, Long M, Sun Z, Yang C, Jiang X, He L, Su L, Peng Z

International immunopharmacology1 Oct 2021Cited by 4 (Europe PMC)

PMID34607232DOI10.1016/j.intimp.2021.108167PepBankPUB-34607232

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Natural levels measured9

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, lower stages of the body's own Tβ4 were correlated with higher odds of acute kidney injury.
In plain wordsIn ICU patients with sepsis, lower levels of the body's own Tβ4 were linked to more kidney injury.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseAcute kidney injury (odds per lower Tβ4 stage)
Study
n = 191
Outcome group
Kidney function · Kidney and urinary
Measurements
Odds ratio
2.102 per stage lower
AKI
Source sentences
Summary
Lower Tβ4 stages were correlated with poor prognosis, including AKI(odds ratio [OR], 2.102 per stage lower; 95% confidence interval [CI], 1.448 to 3.050; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723201
02HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, lower stages of the body's own Tβ4 were correlated with higher odds of continuous renal replacement therapy.
In plain wordsIn ICU patients with sepsis, lower levels of the body's own Tβ4 were linked to more need for kidney replacement therapy.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseContinuous renal replacement therapy (odds per lower Tβ4 stage)
Study
n = 191
Outcome group
Kidney function · Kidney and urinary
Measurements
Odds ratio
2.346 per stage lower
CRRT
Source sentences
Summary
CRRT(OR, 2.346 per stage lower; 95% CI, 1.287 to 4.276; P = 0.005)
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723202
03HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, lower stages of the body's own Tβ4 were correlated with higher odds of 7-day mortality.
In plain wordsIn ICU patients with sepsis, lower levels of the body's own Tβ4 were linked to more deaths within 7 days.
Peptide
Thymosin beta-4 (human)
Outcome
Decrease7-day mortality (odds per lower Tβ4 stage)
Study
n = 191
Outcome group
Mortality · Whole body
Measurements
Odds ratio
1.755 per stage lower
7-day mortality
Source sentences
Summary
7-day mortality(OR, 1.755 per stage lower; 95% CI, 1.050 to 2.935; P = 0.032)
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723203
04HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, lower stages of the body's own Tβ4 were correlated with higher odds of 28-day mortality.
In plain wordsIn ICU patients with sepsis, lower levels of the body's own Tβ4 were linked to more deaths within 28 days.
Peptide
Thymosin beta-4 (human)
Outcome
Decrease28-day mortality (odds per lower Tβ4 stage)
Study
n = 191
Outcome group
Mortality · Whole body
Measurements
Odds ratio
1.821 per stage lower
28-day mortality
Source sentences
Summary
28-day mortality(OR, 1.821 per stage lower; 95% CI, 1.209 to 2.743; P = 0.004).
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723204
05HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, Kaplan-Meier analysis showed that patients with lower Tβ4 stages had a high risk of AKI and death.
In plain wordsIn ICU patients with sepsis, lower levels of the body's own Tβ4 were linked to higher risk of kidney injury and death.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseKaplan-Meier risk of AKI and death by Tβ4 stage
Study
n = 191
Outcome group
Mortality · Whole body
Source sentences
Summary
Kaplan-Meier analysis also demonstrated that patients with lower Tβ4 stages had a high risk of AKI and death.
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723205
06HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, the area under the curve of Tβ4 for predicting AKI was 0.702.
In plain wordsIn ICU patients with sepsis, the body's own Tβ4 level predicted kidney injury with an AUC of 0.702.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 AUC for predicting AKI
Study
n = 191
Outcome group
Kidney function · Kidney and urinary
Measurements
AUC
0.702 AUC
AKI
Source sentences
Summary
In addition, the area under the curve (AUC) of Tβ4 for predicting AKI, CRRT, 7-day mortality, and 28-day mortality were, respectively, 0.702 (95% CI 0.628-0.776), 0.717 (95% CI 0.592-0.842), 0.694 (95% CI 0.579-0.808), and 0.682 (95% CI 0.598-0.767).
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723206
07HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, the area under the curve of Tβ4 for predicting CRRT was 0.717.
In plain wordsIn ICU patients with sepsis, the body's own Tβ4 level predicted the need for kidney replacement therapy with an AUC of 0.717.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 AUC for predicting CRRT
Study
n = 191
Outcome group
Kidney function · Kidney and urinary
Measurements
AUC
0.717 AUC
CRRT
Source sentences
Summary
In addition, the area under the curve (AUC) of Tβ4 for predicting AKI, CRRT, 7-day mortality, and 28-day mortality were, respectively, 0.702 (95% CI 0.628-0.776), 0.717 (95% CI 0.592-0.842), 0.694 (95% CI 0.579-0.808), and 0.682 (95% CI 0.598-0.767).
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723207
08HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, the area under the curve of Tβ4 for predicting 7-day mortality was 0.694.
In plain wordsIn ICU patients with sepsis, the body's own Tβ4 level predicted death within 7 days with an AUC of 0.694.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 AUC for predicting 7-day mortality
Study
n = 191
Outcome group
Mortality · Whole body
Measurements
AUC
0.694 AUC
7-day mortality
Source sentences
Summary
In addition, the area under the curve (AUC) of Tβ4 for predicting AKI, CRRT, 7-day mortality, and 28-day mortality were, respectively, 0.702 (95% CI 0.628-0.776), 0.717 (95% CI 0.592-0.842), 0.694 (95% CI 0.579-0.808), and 0.682 (95% CI 0.598-0.767).
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723208
09HumanEndogenous levelObservational studyOther
In ICU patients with sepsis, the area under the curve of Tβ4 for predicting 28-day mortality was 0.682.
In plain wordsIn ICU patients with sepsis, the body's own Tβ4 level predicted death within 28 days with an AUC of 0.682.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 AUC for predicting 28-day mortality
Study
n = 191
Outcome group
Mortality · Whole body
Measurements
AUC
0.682 AUC
28-day mortality
Source sentences
Summary
In addition, the area under the curve (AUC) of Tβ4 for predicting AKI, CRRT, 7-day mortality, and 28-day mortality were, respectively, 0.702 (95% CI 0.628-0.776), 0.717 (95% CI 0.592-0.842), 0.694 (95% CI 0.579-0.808), and 0.682 (95% CI 0.598-0.767).
1 context sentence(design, population, supporting numbers)
Summary · context
The Tβ4 concentrations were prospectively measured in 191 patients within 6 h of the intensive care units (ICU) admission with diagnosis of sepsis.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3460723209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.